New
from MindBio Therapeutics has found a strong connection between microdosing psychedelics and sleep as it relates to depressive disorders. The clinical trial aimed to examine the role of a particular psychedelic drug known as MB22001 on sleep, as it’s already been proven to benefit mood and energy levels in people with depression.
The connection between sleep and depression
Getting enough good quality sleep is crucial for overall health. During sleep, the body stays active, working to store new information, remove toxic waste, repair cells, and restore energy. If a person doesn’t get enough sleep, these processes are hindered, leading to various issues, including difficulties regulating emotions.
The connection between sleep and depression acts as a catch-22: not enough quality sleep increases the risk for depression and depressive symptoms, but when a person already has depression, they are less likely to get enough shuteye because of how the condition affects the level of restorative sleep a person gets each night.
The study parameters and results
The research surrounding psychedelics and sleep as it pertains to depression used MB22001, a form of LSD, in randomized controlled clinical trials and found that participants were able to get better sleep after microdosing as opposed to those who were in the placebo group.
Participants experienced an average of 24 minutes of extra time spent asleep. While that may not seem like a lot,
and their effects found that getting any extra sleep can significantly impact a person’s ability to regulate their emotions and reduce depressive symptoms.
